Effect of Anti-diabetic Drugs on Glycemic Variability
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 135 participants.
Also called NCT02925559
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 135 participants
- Sponsor
- Registry
-
NCT02925559
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Brazil
- Registry status
- Completed
Technical summary
Registry record NCT02925559. Randomized; no masking; primary purpose treatment. Start 2016-10 (actual); primary completion 2018-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Anti-diabetic Drugs on Glycemic Variability
- Acronym
- EFFORT
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Gliclazide MR
- Lead sponsor
- Centro de Diabetes Curitiba Ltda
- Collaborator
- AstraZeneca
Record details
- Record id
cardio:ct-nct02925559- Content hash
228e9af975eb82a9b4ed2ea1dbf72b2b41c69217e6ce2dbe7d5556022146001c